Transfusion Dose Density Affects Myelodysplastic Syndrome Survival

MONDAY, June 24, 2019 -- Transfusion dose density is an independent prognostic factor for progression-free survival (PFS) in patients with myelodysplastic syndromes treated with red blood cell transfusions (RBCTs), according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news